drugset / Trial / NCT04729348
Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research is to examine if an experimental drug combination impacts the survival rate of individuals with Leptomeningeal Metastases This research study involves an experimental drug combination. The names of the study drugs involved in this study are: * Pembrolizumab * Lenvatinib
Timeline
- Start
- 2021-03-08
- Primary completion
- 2024-01-17
- Completion
- 2024-01-17
Outcome
Outcome not reported
Stopped: “Planned interim analysis”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | — | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | — | Oral |